Cancer
📧 Sign up to get email alerts when something new happens for Cancer.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2025-08-12EMA Authorised: Dyrupeg (pegfilgrastim) — CuraTeQ Biologics s.r.o
EMA authorises Dyrupeg (pegfilgrastim) by CuraTeQ Biologics for use in neutropenia and cancer indications.
-
EMA approval · 2025-08-11EMA Authorised: Zometa (zoledronic acid;zoledronic acid monohydrate) — Phoenix Labs Unlimited Company
The EMA has authorised Zometa (zoledronic acid) for cancer and bone-related indications, with Phoenix Labs Unlimited Company as the marketin…
-
EMA approval · 2025-07-08EMA Authorised: Filgrastim Hexal (filgrastim) — Hexal AG
EMA authorised Filgrastim Hexal (filgrastim), a biosimilar granulocyte colony-stimulating factor, for neutropenia management in cancer patie…
-
EMA approval · 2025-07-08EMA Authorised: Zarzio (filgrastim) — Sandoz GmbH
The EMA authorised Zarzio, a filgrastim biosimilar from Sandoz GmbH, for use in hematopoietic stem cell transplantation and cancer indicatio…
-
EMA approval · 2025-05-02EMA Authorised: NeoRecormon (epoetin beta) — Roche Registration GmbH
The EMA authorised NeoRecormon (epoetin beta) from Roche Registration GmbH for multiple indications, including chronic kidney disease–relate…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2024-12-02EMA Authorised: Sancuso (granisetron) — Grünenthal GmbH
The EMA authorised Sancuso, a granisetron transdermal patch from Grünenthal GmbH, for the prevention of vomiting in cancer patients.
-
EMA approval · 2024-08-30EMA Authorised: Ratiograstim (filgrastim) — Ratiopharm GmbH
EMA authorised Ratiograstim (filgrastim) by Ratiopharm GmbH for cancer and hematopoietic stem cell transplantation to reduce chemotherapy-in…
-
EMA approval · 2024-08-30EMA Authorised: Tevagrastim (filgrastim) — Teva GmbH
The EMA authorised Tevagrastim (filgrastim) by Teva GmbH for cancer-related indications (and related hematopoietic stem cell transplantation…
-
EMA approval · 2024-08-30EMA Authorised: Iasibon (ibandronic acid) — Pharmathen S.A.
EMA authorised Iasibon (ibandronic acid) for hypercalcemia, prevention of bone fractures, and cancer-related indications involving metastati…
-
EMA approval · 2024-06-05EMA Authorised: PecFent (fentanyl) — Gruenenthal GmbH
EMA authorised PecFent (fentanyl) by Gruenenthal GmbH for pain management, with therapeutic areas including Pain and Cancer (decision date 1…
-
FDA approval · 2023-10-13FDA Approved: FULPHILA — Supplemental Application (Biocon Biologics Inc.)
FDA approved a supplemental Biologics License Application for FULPHILA (pegfilgrastim-jmdb) by Biocon Biologics Inc.
-
EMA approval · 2023-09-27EMA Authorised: Eporatio (epoetin theta) — Ratiopharm GmbH
Authorised status for Eporatio (epoetin theta) by Ratiopharm GmbH for treatment areas including chronic kidney failure, anemia, and cancer.
-
EMA approval · 2023-09-27EMA Authorised: Biopoin (epoetin theta) — Teva GmbH
Biopoin (epoetin theta) has been authorised by the EMA for indications including chronic kidney failure, anemia, and cancer.
-
EMA approval · 2023-02-24EMA Authorised: Aloxi (palonosetron hydrochloride) — Helsinn Birex Pharmaceuticals Ltd.
Aloxi (palonosetron hydrochloride) has been authorised in the EU for use related to vomiting and cancer indications.
-
EMA approval · 2022-05-24EMA Authorised: Amifampridine SERB (amifampridine phosphate) — SERB SA
European Medicines Agency authorises amifampridine phosphate (SERB) for various neuromuscular and autoimmune conditions, with Lambert-Eaton …
-
FDA approval · 2022-05-02FDA Approved: EMEND — Supplemental Application (Merck Sharp & Dohme LLC)
The FDA approved a supplemental application for EMEND (fosaprepitant dimeglumine) from Merck Sharp & Dohme LLC, updating the drug's regulato…
-
EMA approval · 2020-11-25EMA Authorised: Silapo (epoetin zeta) — Stada Arzneimittel AG
Silapo (epoetin zeta) has been authorised by the EMA for indications related to anemia associated with chronic kidney disease, cancer, and u…
-
FDA approval · 2020-10-22FDA Approved: LEUCOVORIN CALCIUM — Original Application (Leading Pharma, LLC)
The FDA approved Leucovorin Calcium from Leading Pharma, LLC under ANDA 213929 via an Original Application, establishing a new generic produ…
-
FDA approval · 2020-06-10FDA Approved: NYVEPRIA — Original Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved NYVEPRIA (pegfilgrastim-APGF) from Pfizer in an original biologics application, establishing a pegfilgrastim biosimilar therapy…
-
FDA approval · 2020-02-12FDA Approved: UDENYCA — Supplemental Application (Accord BioPharma, Inc.)
FDA approved a supplemental Biologics License Application for UDENYCA (pegfilgrastim-cbqv) submitted by Accord BioPharma, Inc., expanding it…
-
FDA approval · 2020-02-10FDA Approved: FOSAPREPITANT — Supplemental Application (Novadoz Pharmaceuticals LLC)
FDA approved a supplemental application for fosaprepitant submitted by Novadoz Pharmaceuticals LLC to expand its labeling.
-
FDA approval · 2019-09-06FDA Approved: MESNA — Supplemental Application (Gland Pharma Limited)
FDA approved a supplemental application for MESNA Injection from Gland Pharma Limited, validating its manufacture and labeling for this gene…
-
FDA approval · 2019-05-29FDA Approved: FULPHILA — Supplemental Application (Biocon Biologics Inc.)
FDA approved a supplemental application for Fulphila (pegfilgrastim-jmdb) from Biocon Biologics Inc., expanding its regulatory status.
-
FDA approval · 2019-04-16FDA Approved: UDENYCA — Supplemental Application (Accord BioPharma, Inc.)
FDA approved a supplemental application for UDENYCA (pegfilgrastim-cbqv) from Accord BioPharma, authorizing a new or expanded use for the pr…
-
FDA approval · 2019-03-28FDA Approved: GRANIX — Supplemental Application (Cephalon, LLC)
FDA approved a supplemental application for GRANIX (tbo-filgrastim) submitted by Cephalon, LLC.